1. Home
  2. FISI vs ESPR Comparison

FISI vs ESPR Comparison

Compare FISI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FISI

Financial Institutions Inc.

HOLD

Current Price

$38.51

Market Cap

713.0M

Sector

Finance

ML Signal

HOLD

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.17

Market Cap

816.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FISI
ESPR
Founded
1817
2008
Country
United States
United States
Employees
631
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.0M
816.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FISI
ESPR
Price
$38.51
$3.17
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$37.00
$8.75
AVG Volume (30 Days)
219.8K
8.9M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.76%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.22
$12.81
P/E Ratio
$9.36
N/A
Revenue Growth
N/A
21.31
52 Week Low
$24.62
$1.10
52 Week High
$40.26
$4.18

Technical Indicators

Market Signals
Indicator
FISI
ESPR
Relative Strength Index (RSI) 59.15 64.61
Support Level $36.43 $3.16
Resistance Level N/A $3.18
Average True Range (ATR) 0.93 0.02
MACD -0.03 -0.01
Stochastic Oscillator 58.73 87.50

Price Performance

Historical Comparison
FISI
ESPR

About FISI Financial Institutions Inc.

Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: